

# Friday, 2<sup>nd</sup> February 2024

| Time            | Programme                     |
|-----------------|-------------------------------|
| 08:30 - 09 : 15 | Registration & Welcome Coffee |

DISCOVERY AND INNOVATION TRACK Exploring innovations for Next-generation Cell and Gene Therapies Chairperson: Dr. Navin Khattry, ACTREC, TMC & Dr. Jyoti Anand Kode, ACTREC, Tata Memorial Centre .

| Time         | Title  | Speaker   |
|--------------|--|---|
| 9:15 - 9:40  | Tailored Gene Therapies Targeting Sickle Cell Anaemia                                      | <b>Dr. Akshay Sharma,</b><br>St. Jude Children's Research Hospital, USA |
| 9:40 - 10:05 | Development of effective Pre-clinical animal models to<br>predict outcomes in Human Trials | <b>Dr. Wayne A. Marasco</b><br>Harvard Medical School, USA              |
| 10:05-10:30  | Harnessing Gene Therapy for Hemophilia and the Progress in India                           | <b>Dr. Alok Srivastava</b><br>Christian Medical College, Vellore, India |

### 10:30 - 10:35

Q & A

Fire Side Panel Discussion Accelerating Innovation-A Roadmap for India Moderated by-Dr. Akrasubhra Ghosh, Narayan Nethralaya Eye Hospital

| Time          | Speaker   | Speaker   |
|---------------|---|---|
|               | <b>Dr. Rahul Purwar</b><br>IIT Bombay, ImmunoACT, Mumbai, India                                       | <b>Dr. Raghu Padinjat</b><br>National Centre for Biological Sciences (NCBS), Bangalore, India |
| 10:35-11:05   | <b>Dr. Sivaprakash Ramalingam -</b> Institute of Genomics and Integrative Biology (CSIR), Delhi India | Dr. Shashwati Basak<br>Intas Pharmaceuticals, Ahmedabad, India                                |
|               | Dr. Alok Srivastava<br>Christian Medical College, Vellore, India                                      |   |
| 11:05 - 11:20 | Coffee Break  |   |



3<sup>rd</sup>

**SACT 2024** 

**SCIENTIFIC** 

AGENDA

| 11:20 - 11:45   | INAUGURATION CEREMONY  |   |  |
|---|--|---|--|
|   | Opening Remarks  | Dr. Albeena Nisar, Organizing Secretary- SACT, ACTREC, TM   |  |
|   | Welcome Address  | Dr. Navin Khattry, Deputy Director, CRC, ACTREC, TMC  |  |
|   | Address by the Chairman of Scientific Committee  | Dr. (Surg Cdr) Gaurav Narula, Chairman of Scientific Committee-SA   |  |
| 11:20 - 11:45   | Remarks  | Dr. Prasanna Venkataraman, Deputy Director, CRI, Mumb   |  |
| 11.20 - 11.40   | Address by the Chief Guest   | Dr. Jitendra Kumar, MD, DBT- BIRAC, New Delhi, India  |  |
|   | Vote of Thanks Dr. Albeena Nisar   |   |  |
|   | Lighting of Lamp & Inauguration  |   |  |
|   | Special Address: The Concept of Innovation and<br>Orchestration: "Translating Therapies from Bench to<br>Bedside"  | Dr. Khalid Shah, Harvard Medical School, USA  |  |
| Chairpersons: Dr. Nirali S  | <sup>r</sup> Process Optimization & Analytics For Faster Approval<br>hah, NCI & Dr (Lt Col)Pawan Gupta, Stempeutics  |   |  |
| Time  | Title  | Speaker   |  |
|   | Novel Manufacturing Process: CAR-T cell expansion platforms<br>yield distinct T cell differentiation statesDr. Steven Highfill<br>National Cancer Institute, USA   |   |  |
| 11:45 - 12:10   |  |   |  |
| 11:45 - 12:10<br>12:10 - 12:35  |  | National Cancer Institute, USA  |  |
|   | yield distinct T cell differentiation states   | National Cancer Institute, USA           Mr. Srinidhi Deshpande   |  |
| 12:10 - 12:35<br><b>12:35 - 12:40</b><br>Fire Side Panel Discussion<br>Planning Better for Faster                     | yield distinct T cell differentiation states<br>Buy vs Build Manufacturing- Autologous CAR T Thera<br>Q & A  | National Cancer Institute, USA Apy Mr. Srinidhi Deshpande   |  |
| 12:10 - 12:35<br><b>12:35 - 12:40</b><br>Fire Side Panel Discussion<br>Planning Better for Faster                     | yield distinct T cell differentiation states<br>Buy vs Build Manufacturing- Autologous CAR T Thera<br>Q & A<br>on<br>Approvals   | National Cancer Institute, USA           Mr. Srinidhi Deshpande   |  |
| 12:10 - 12:35<br>12:35 - 12:40<br>Fire Side Panel Discussion<br>Planning Better for Faster<br>Moderated by - Dr. Uday | yield distinct T cell differentiation states<br>Buy vs Build Manufacturing- Autologous CAR T Thera<br>Q & A<br>on<br>Approvals<br>Kumar Kolkundkar Stempeutics   | National Cancer Institute, USA       apy       Mr. Srinidhi Deshpande       Cytiva, CCRM, Canada  |  |
| 12:10 - 12:35<br>12:35 - 12:40<br>Fire Side Panel Discussion<br>Planning Better for Faster<br>Moderated by - Dr. Uday | yield distinct T cell differentiation states<br>Buy vs Build Manufacturing- Autologous CAR T Thera<br>Q & A<br>on<br>Approvals<br>Kumar Kolkundkar Stempeutics<br>Dr. Raviraja N. S.<br>Manipal Academy of Higher Education, | National Cancer Institute, USA         apy       Mr. Srinidhi Deshpande         Cytiva, CCRM, Canada         Speaker         Dr. Atharva Karulkar |  |



40.40 40.00

|   | Showcase Presentation- Thermo Fisher Scientific   |  |
|---|---|--|
| Time  | Tittle  | Speaker  |
| 13:10-13:35   | Cell and Gene Therapy Solutions: Recent technical innovations that facilitate manufacturing steps in the CAR-T cell workflow  | <b>Dr. Roland Leathers</b><br>Senior Manager, Thermo Fisher Scientific   |
| 13:35 - 14:30   | LUNCH & POSTER WALK   |  |
|   | Cell therapy for Solid Tumors & Beyond<br>Chinaswamy, Tata Memorial Hospital & Dr. Prasanna Venka   | atraman, ACTREC  |
| Time  | Tittle  | Speaker  |
| 14:30-14:55   | Gene Edited and Engineered Tumor cells:<br>A New Immunotherapeutic Approach for Cancer  | <b>Dr. Khalid Shah</b><br>Harvard Medical School, USA  |
| 14:55 - 15:20   | Cellular Immunotherapies for Virus-associated<br>Cancers and Post-transplant Infectious Complications   | <b>Dr. Rajiv Khanna</b><br>QIMR Berghofer Medical Research Institute, Australia  |
| 15:20 - 15:45   | Next-generation CARs- Targeting Solid Tumours taking<br>into consideration the Tumour Microenvironment  | Dr. Avery Posey<br>Perelman School of Medicine, University of Pennsylvania, L  |
|   |   |  |
| 15:45 - 15:50   | Q & A   |  |
| <b>Fire Side Panel Discuss</b> i<br>Breaking "Solid" Barriers                             | Q & A<br>on   |  |
| <b>Fire Side Panel Discuss</b> i<br>Breaking "Solid" Barriers                             | Q & A<br>on<br>to Cell/ Gene Therapy  | Speaker  |
| Fire Side Panel Discussi<br>Breaking "Solid" Barriers<br>Moderated by: Dr. Albeer         | Q & A<br>on<br>to Cell/ Gene Therapy<br>na Nisar, ACTREC, Tata Memorial Centre  |  |
| Fire Side Panel Discussi<br>Breaking "Solid" Barriers<br>Moderated by: Dr. Albeer         | Q & A<br>on<br>to Cell/ Gene Therapy<br>ha Nisar, ACTREC, Tata Memorial Centre<br>Speaker<br>Dr. Shailendra Upraity   | Speaker<br>Dr. Rajiv Khanna  |
| Fire Side Panel Discussi<br>Breaking "Solid" Barriers<br>Moderated by: Dr. Albeen<br>Time | Q & A         on         to Cell/ Gene Therapy         na Nisar, ACTREC, Tata Memorial Centre         Speaker         Dr. Shailendra Upraity         Aurigene Pharmaceutical Services Limited, Banglore, India         Dr. Khalid Shah  | Speaker<br>Dr. Rajiv Khanna<br>QIMR Berghofer Medical Research Institute, Australia<br>Dr. Rajarshi Pal<br>Eyestem Research, C-CAMP, Bengaluru, India<br>Dr. Avery Posey |
| Fire Side Panel Discussi<br>Breaking "Solid" Barriers<br>Moderated by: Dr. Albeen<br>Time | Q & A         on         to Cell/ Gene Therapy         na Nisar, ACTREC, Tata Memorial Centre         Speaker         Dr. Shailendra Upraity         Aurigene Pharmaceutical Services Limited, Banglore, India         Dr. Khalid Shah         Harvard Medical School, USA         Dr. Vainav Patel | Speaker<br>Dr. Rajiv Khanna<br>QIMR Berghofer Medical Research Institute, Australia<br>Dr. Rajarshi Pal<br>Eyestem Research, C-CAMP, Bengaluru, India                    |

Thormo Fisher Colontif

Chauseasa Duesentation



# Regulatory TRACK

From First In Human to Speeding up to Clinical Trials

Chairpersons: Dr. Shripad D. Banavali, Tata Memorial Centre & Dr. Stephan Grupp, CHOP, USA

| Time   | Title  | Speaker  |
|--|--|--|
| 16:50-17:15  | Regulatory Advice to Guide the Development of the Next Wave of Cell Therapies  | <b>Dr. Peter Marks</b><br>Director, Center for Biologics Evaluation & Research (CEBR) FE |
|  | Regulatory Frameworks for Cell Therapies<br>II) Pawan Kumar Gupta, Stempeutics Research Pvt Ltd, Bar   | ngalore, India   |
| Time   | Speaker  | Speaker  |
|  | <b>Dr. Peter Marks</b><br>Director, Centre for Biologics Evaluation & Research (CEBR) FDA, USA   | <b>Dr. Geeta Jotwani</b><br>Senior Deputy Director General, ICMR New Delhi, India        |
| 17:15- 17:45   | <b>Dr. Subrata Sinha</b><br>All India Institute of Medical Sciences (AIIMS), New Delhi, India  | <b>Dr. Rajiv Khanna</b><br>QIMR Berghofer Medical Research Institute, Australia          |
|  | Dr. Yogendra Kumar Gupta<br>AIIMS Bhopal, AIIMS Jammu,Medical Advisor at VaidyaRx,New Delhi, India.  | <b>Dr. Annu Uppal</b><br>US Pharmacopeia, Hyderabad, India                               |
|  |  |  |
| Č ,  | oportunities Track<br>ture of Cell Therapy in India: The Trajectory of Future Invest<br>dra Kumar, DBT BIRAC, New Delhi, India   | ment.  |
| Paving the way for the Fut   | ture of Cell Therapy in India: The Trajectory of Future Invest   | rment.<br>Speaker  |
| Paving the way for the Fut<br>CHAIRPERSON: Dr. Jiten   | ure of Cell Therapy in India: The Trajectory of Future Invest<br>dra Kumar, DBT BIRAC, New Delhi, India  | Speaker<br>Dr. Anand Covindaluri   |
| Paving the way for the Fut<br>CHAIRPERSON: Dr. Jiten<br>Time<br>17:45-18:10<br>Fire Side Panel Discussi<br>Fire Side Leadership Pane<br>Moderated by Dr. Anand | ture of Cell Therapy in India: The Trajectory of Future Invest<br>dra Kumar, DBT BIRAC, New Delhi, India<br>Title<br>Catalyzing Investments in Cell & Gene therapy Industry<br>ion<br>el Discussion<br>Govindaluri, Govin Capital, Singapore | Speaker       Dr. Anand Govindaluri       Govin Capital, Singapore                       |
| Paving the way for the Fut<br>CHAIRPERSON: Dr. Jiten<br>Time<br>17:45-18:10<br>Fire Side Panel Discussi<br>Fire Side Leadership Pane                           | ture of Cell Therapy in India: The Trajectory of Future Invest<br>dra Kumar, DBT BIRAC, New Delhi, India<br>Title<br>Catalyzing Investments in Cell & Gene therapy Industry<br>ion<br>el Discussion  | Speaker<br>, Dr. Anand Govindaluri   |



|  | <b>Dr. Raj K Shirumalla</b><br>National Biopharma Mission, BIRAC, New Delhi, India | Dr. Mohammad Atif Alam<br>Centre for Cellular and Molecular Platforms, Bangalore, India |
|--|--|---|
| 18:10-18:40  | <b>Dr. Dinesh Kundu</b><br>East Ocyon Bio Private Limited Gurugram, India.         |   |
| 19:00 Onwards                                      | Gal  | la Dinner   |
| aturday, 3 <sup>™</sup> Februa                     | ary 2024 <b>D</b> AY <b>2</b>  |   |
| Time   |  | rogramme  |
| 08:30 - 9:00                                       | Cof  | fee/Breakfast   |
| AR-T Cells for Hematoly<br>ssion 1:<br>airpersons: |  |   |
|  | MER, Chandigarh, India & Dr. Swaminathan Iyer, MD Anders                           |   |
| . Pankaj Malhotra, PGIN<br>Time<br>09:00-09:25     |  | Speaker   |
| Time   | Title The Landscape of CD19-directed CAR T Therapies for                           | Speaker<br>Dr. Hasmukh Jain   |

| 10:15-10:20   | Q & A             |
|---------------|-------------------|
|               |                   |
| 10:20 - 10:35 | Tea/ Coffee break |



Session 2 - Paediatric ALL: The CAR-T Cell Role Model Chairpersons: Dr. Shripad D. Banavali, Tata Memorial Centre & Dr. Revathi Raj, Apollo Hospitals Cancer Centre Nandanam, Chennai, India

| Time          | Title   | Speaker   |
|---------------|---|---|
| 10:35 - 10:50 | Emily Whitehead- The Story that Sailed Triggered a Cell Therapy Revolution Emily Whitehead Foundation, USA  |   |
| 10:50-11:15   | Building Better CAR T Therapies - Reflections of<br>emergent challenges over a decade of CAR T cell therapy | <b>Dr. Stephan A. Grupp</b><br>Children's Hospital of Philadelphia, USA |
| 11:15-11:40   | Replacing chemotherapy with immune therapy in children and young persons with ALL                           | <b>Dr Ajay Vora</b><br>University of Sheffield, UK                      |
| 11:40-12:05   | First in Canada CAR-T Cell Therapy-<br>Building Low Cost and Equitable Treatment Capacity                   | <b>Dr. Kevin Hay Terry</b><br>Fox Laboratory, Canada                    |

#### **Fire Side Panel Discussion**

Integrating CAR T- Cells into Treatment Algorithms in India- Paving The Road Ahead **Moderated by** Dr. Gaurav Narula, Tata Memorial Hospital, TMC

| Time  | Speaker  |                                   | Speaker   |
|---|--|-----------------------------------|---|
|   | Dr. Akanksha Chichra<br>Tata Memorial Centre, Mumbai, India        | Dr.Sharat Dam<br>Narayana Healt   | <b>odar</b><br>h, Bangalore, India  |
| 12:05-12:35                                   | <b>Dr Bhausaheb Bagal</b><br>Tata Memorial Hospital, Mumbai, India | Dr. Nirali Shah<br>National Cance |   |
|   | Dr. Stephan A. Grupp<br>Children's Hospital of Philadelphia, USA   | Dr Ajay Vora<br>University of Sh  | neffield, UK  |
| 12:35 - 13:35                                 | LUNCH & POSTER WALK  |                                   |   |
| owcase Presentation<br>airperson: Dr. Manoj I | Mahimkar, ACTREC, Mumbai, India                                    |                                   |   |
| . Vikaramjit Kanwar, H                        | lomi Bhabha Cancer Hospital, Varanasi, India                       |                                   | L Contraction of the second |
| : Vikaramjit Kanwar, H<br>13:35 - 14:00       | Key Learnings from the Scale-Up of Pivotal Trial                   | in DLBCL                          | Dr. Anna Wijatyk, Miltenyi Biomedicine  |



## **CLINICAL TRACK**

Monitoring & Measuring: Maximising Clinical Outcome with CAR-T Cell Therapy **Chairpersons:** Dr. P.G. Subramanian, ACTREC and Dr. Reena Das, PGI Chandigarh

| Time          | Title  | Speaker   |
|---------------|--|---|
| 14:25-14:50   | Monitoring of Circulating CAR T Cells: Validation of a Flow<br>Cytometric Assay, Cellular Kinetics, and Phenotype Analysis | <b>Dr. Gaurav Chatterjee</b><br>ACTREC, Mumbai, India         |
| 14:50 - 15:15 | Third Party Virus Specific T-Cells Post Allogenic Transplant   | <b>Dr. Nishant Jindal,</b><br>ACTREC, Mumbai, India           |
| 15:15 - 15:40 | Off the shelf CAR-T approaches for Lymphoma  | <b>Dr. Swaminathan lyer</b><br>MD Anderson Cancer Center, USA |

| 15:45 - 15:55 | TEA BREAK |
|---------------|-----------|
|               |           |

15:55 - 16:15 Oral Poster Presentation

Fire Side Panel Discussion All Tools in One Box Moderated by Dr. Chetan Dhamne, ACTREC, TMC

| Time          | Title   | Speaker  |
|---------------|---|--|
| 16:15 - 16:45 | <b>Dr. Pankaj Malhotra</b><br>PGIMER, Chandigarh, India | <b>Dr. Nikhil Patkar</b><br>Tata Memorial Centre, Mumbai, INDIA                        |
|               | <b>Dr. Kevin Hay</b><br>Terry Fox Laboratory, Canada    | <b>Dr. Sameer Bakhshi</b><br>All India Institute of Medical Sciences, New Delhi, INDIA |
|               | <b>Dr. Gaurav Chatterjee</b><br>ACTREC, Mumbai, India   | <b>Dr. Carlos Fernandez de Larrea</b><br>University of Barcelona, Barcelona, Spain     |



3<sup>rd</sup>

**SACT 2024** 

**SCIENTIFIC** 

AGENDA

## COMMERCIALIZATION TRACK

The trajectory of future investment and easy patient accessibility mode

Fire Side Panel Discussion

Think Tank-Industry

Moderated by Dr. Anand Govindaluri, Govin Capital, Singapore

| Time          | Speaker   | Speaker   |
|---------------|---|---|
| 16:45 - 17:15 | <b>Dr. Murali Ramachandra</b><br>Aurigene Oncology, Bangalore, India. | <b>Dr. Mahesh Bhalgat</b><br>Syngene International Limited, Bangalore, India  |
|               | <b>Mr. Shirish Arya</b><br>ImmunoACT, Mumbai, India                   | <b>Dr. Samir Kulkarni</b><br>Institute Of Chemical Technology, Mumbai, India. |
|               | Dr. Jeevan Ghosalkar - Cipla Limited, Mumbai, India                   |   |

# PATIENT ADVOCACY TRACK

Equity, Access & Affordability of Cell Therapies

| Time          | Title   | Speaker   |  |
|---------------|---|---|--|
| 17:15 - 17:45 | Fire Side Panel Discussion with leading Oncologists,<br>Patient Solution Focused Agencies and Patient Advocate groups | <i>Moderated by</i><br><b>Ms. Shalini Jatia</b> Impact Foundation |  |
| 17:45 - 18:15 | Valedictory   |   |  |
|               | Closing Remarks   |   |  |